PharmaResearch Re-Rating Check: Can Rejuran Move From Medical Device Monopoly to U.S. Derma-Cosmetics Platform?
Pamicell (005690) Part 3 — 1Q26 Earnings Confirmation: Revenue ₩36.7bn, OP ₩13.1bn, OPM 35.7%. Above Consensus on All Lines
Pamicell (005690) Series Part 2 — The Four-Layer Recognition Gap Closing, and the New 'Fifth Layer' of a 12–24 Month Industry Cycle
OpenEdges Technology (394280) — Is OpenEdges Publicly Traded? Korea's Most Direct Alpha on LPDDR Becoming AI Inference Server Memory